poisar

Stocks · News reference

Pacira BioSciences Q2 Adj. EPS $0.73 Beats $0.65 Estimate, Sales $192.400M Beat $190.816M Estimate

Aug 4, 2026, 8:02 PMBenzinga Newsdesk

Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.65 by 12.31 percent. This is a 1.35 percent decrease over earnings of $0.74 per share from

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

PCRX
Source
benzinga
Observed
Aug 4, 2026, 8:02 PM
Checked
Aug 4, 2026, 8:02 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 6, 2026, 12:16 PMBenzinga Newsdesk

    Pacira Biosciences Publishes 2-Yr Phase 1 Results In Annals Of Rheumatic Diseases For PCRX-201 Gene Therapy In Moderate To Severe Knee Osteoarthritis, Showing Tolerability And Improvements In Pain, Stiffness, And Function

    — A single locally administered intra-articular injection of PCRX-201 into the knee was well tolerated in patients with moderate-to-severe knee osteoarthritis —— Exploratory clinical outcome measures showed improvements

    Read original at benzinga
    PCRX